drugset / Trial / NCT07575893
CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma
Phase 1
Not yet recruiting
12 enrolled
New York Medical College
Memorial Sloan Kettering Cancer Center · collabUniversity of North Carolina · collab
NaSingle-groupOpen-labelTreatment
Summary
Patients with relapsed low-risk CD30 classical Hodgkin Lymphoma will have autologous CD30 CAR T-cell manufactured. Dose escalation will be used to determine the RP2D. Following lymphodepletion, CAR T-cell will be infused.
Timeline
- Start
- 2026-10-01
- Primary completion
- 2031-12-01
- Completion
- 2032-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD30+ CAR T-cells | Cell therapy | — | Intravenous |
| Background | Bendamustin | Unknown | 70 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |